2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1588

Increased Fracture Risk in Patients with Early Rheumatoid Arthritis: A Prospective General Population-Matched Cohort Study
Abstract Number: 1589

Impact of Osteoarthritis of the Hand on Disease Activity Scores and Health Status in Patients with Rheumatoid Arthritis
Abstract Number: 1590

Rheumatoid Arthritis-Related Interstitial Lung Disease (RA-ILD): Methotrexate and the Extension of Lung Disease Are Associated to Prognosis
Abstract Number: 1591

A Low Adiponectin Level in Rheumatoid Arthritis Is Associated with Coronary Artery Disease
Abstract Number: 1592

Sex Differences in Cardiovascular Risk Factors and Event Rates in Patients with Rheumatoid Arthritis – Data from 13 Rheumatology Centers
Abstract Number: 1593

Telomere Length and Cardiovascular Risk in Rheumatoid Arthritis
Abstract Number: 1594

No Association of Anti-Citrullinated Peptide Antibodies with Coronary Artery Calcification in Two Rheumatoid Arthritis Cohorts without Clinical Cardiovascular Disease
Abstract Number: 1595

Impaired Coronary Flow Reserve in Rheumatoid Arthritis: A Robust Indicator of Cardiac Structure Associated with Systemic Inflammation and Rheumatoid Arthritis Treatments
Abstract Number: 1596

Diagnosis of Carotid Plaque By 4 Cardiovascular Risk Scores in Rheumatoid Arthritis
Abstract Number: 1597

Variability in Health Assessment Questionnaire Based on Type of Health Insurance Coverage and Rheumatology Practice
Abstract Number: 1598

Obesity and the Risk for Development of Rheumatoid Arthritis – Results from a Population-Based Nested Case-Control Study
Abstract Number: 1599

Clinical Characteristics of Interstitial Lung Disease (ILD) in Rheumatoid Arthritis (RA) Patients in High Resolutional CT (HRCT) and Titer of Anti Citrullinated Peptide Antibodies (anti-CCP2)
Abstract Number: 1600

Pulmonary Manifestations in Early Rheumatoid Arthritis: A 6 Month Follow up Study
Abstract Number: 1601

Evaluation of Glucose Metabolism in Rheumatic Patients: A Case Control Study
Abstract Number: 1602

Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].